CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 2,385	$ 5,571
Marketable securities, current	1,885	1,864
Receivables	4,299	3,390
Inventories	1,221	1,560
Deferred income taxes, current		1,644
Prepaid expenses and other	491	470
Assets held-for-sale	134	109
Total Current Assets	10,415	14,608
Property, plant and equipment	4,412	4,417
Goodwill	6,881	7,027
Other intangible assets	1,419	1,753
Deferred income taxes	2,844	915
Marketable securities, noncurrent	4,660	4,408
Other assets	1,117	621
Total Assets	31,748	33,749
Current Liabilities:
Short-term borrowings	139	590
Accounts payable	1,565	2,487
Accrued expenses	2,759	2,459
Deferred income, current	1,003	1,167
Accrued rebates and returns	1,324	851
Income taxes payable, current	572	262
Dividends payable	655	645
Total Current Liabilities	8,017	8,461
Pension, postretirement, and postemployment liabilities	949	1,115
Deferred income, noncurrent	586	770
Income taxes payable, noncurrent	742	560
Other liabilities	480	618
Long-term debt	6,550	7,242
Total Liabilities	$ 17,324	$ 18,766
Commitments and contingencies (Note 22)
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 4,161 in 2015 and 4,212 in 2014, liquidation value of $50 per share	$ 0	$ 0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2015 and 2014	221	221
Capital in excess of par value of stock	1,459	1,507
Accumulated other comprehensive loss	(2,468)	(2,425)
Retained earnings	31,613	32,541
Less cost of treasury stock - 539 million common shares in 2015 and 547 million in 2014	(16,559)	(16,992)
Total Bristol-Myers Squibb Company Shareholders' Equity	14,266	14,852
Noncontrolling interest	158	131
Total Equity	14,424	14,983
Total Liabilities and Equity	$ 31,748	$ 33,749